Oil for Life to Balance omega-3 polyunsaturated fatty acids ... - Oil4Life

Supplementation with omega-3 were linked to an increase of vigour and a decrease of
negative factors such as anger, anxiety and depression. These results confirm the influence of
omega-3 on the central nervous system. They are also in line with the suggested action of
these compounds on dementia, depression and mood disorders, in which they may act as
mood. The results suggest that some of these effects are due almost exclusively to diet, e.g
the reduction of body fat, while others, such as the mood state variations, are mainly due to
omega-3 supplementation and the strong antioxidant defence built into Oil4Life Balance.
About 7% of children between the ages of 5-11 years have been diagnosed with Attention
Deficit Hyperactivity Disorder (ADHD). It is one of most common neurodevelopmental
syndrome of childhood. The symptoms should present itself for at least six months before the
age of 7 years, accompanied by “clinically significant” impairment. The current consensus is
that no biochemical tests can reliably predict ADHD. However, a genetic feature of ADHD
is strongly suggested because the syndrome clusters in families, and two polymorphisms in
the dopamine transporter and receptor genes have been identified that seem to influence the
risk of ADHD. General consensus is that many other genes are probably involved in the
transmission of the disorder.
One hypothesis of the etiology of ADHD is concerned with the role of prostaglandins in the
dopaminergic synapses. According to this hypothesis, ADHD is caused or worsened by a
deficiency of Prostaglandin E1 (PGE1), which is again caused by the lack of the enzyme
Δ-6-desaturase. Also environmental toxicant (lead) might be an etiologic risk factor for
ADHD, as is cigarette smoking during pregnancy. Diet may also be an ethiological risk
factor for ADHD. Abnormalities in PUFA metabolism in red blood cell membranes has been
reported in children with ADHD. Children with ADHD have lower levels of long chain
omega-3 fatty acids (EPA+DHA) in their blood, probably due to lack of dietary intake in
conjunction with a more rapid metabolism. Our studies have highlighted a deficiency of the
long chain omega-3 fatty acids in the membrane phospholipids of patients affected with
ADHD. Furthermore, the ratio of AA/EPA in phospholipids both in blood and in RBC seems
to be elevated. The elevated AA/EPA ratio indicates an increased upstream inflammatory
potential. In our study of 30 children with ADHD the diet were supplemented with 2.5 mg
/10 kg/day of EPA+DHA 2:1 as in Oil4Life Balance. The supplementation of EPA and
DHA in relatively high doses compared to body weight, verified that an improved AA/EPA
balance in the cell membrane increased attention level and decrease both hyperactivity levels
and impulsiveness. There was a correlation between the dose of long chain omega-3 fatty
acids, the decrease of AA/EPA ratio and/or the entity of the clinical improvement (score).
Depletion of omega-3 fatty acid levels in red blood cell membranes of depressed patients has
been reported. A significant positive relationship was observed between the severity of the
illness and the ratio of arachidonic acid to eicosapentaenoic acid in serum phospholipids and
in erythrocyte membranes. Preliminary results in our laboratory on depressed elderly patients
demonstrated that counteracting and balancing high levels of AA with EPA+DHA 2:1, as in
Oil4Life Balance, also decreased depression symptoms. Several authors have also reported
lower concentrations of erythrocyte essential fatty acids among schizophrenic patients as
compared with control. DHA is the major acid of neurological and retinal membranes. It
makes up more than 30% of the structural lipids of the neuron. Low levels of circulating
DHA may be a significant risk in the development of Alzheimer dementia. The inability to
maintain a high level of DHA may be due to a reduced capacity to synthesise DHA late in
life, as the result of a reduction in Δ-6-desaturase activity. Alterations in phospholipids,
12